国际皮肤性病学杂志    2007 33 (6): 346-348   ISSN: 2096-5540  CN: 32-1880/R   T淋巴细胞及细胞因子与银屑病的发病关系 雷漾, 郑和义 中国医学科学院北京协和医院皮肤科, 100730 收稿日期 2007-05-09  修回日期 null  网络版发布日期 null 参考文献  [1] Nickoloff BJ.The search for pathogenic T cells and the genetic basis of psoriasis using a severe combined immunodeficient mouse model.Cutis,2000,65(2):110-114. [2] Zhu KJ,Cheng H,Man XH,et al.Increased endocytic activity in monocyte-derived dendritic cells in patients with psoriasis vulgaris.Indian J Med Res,2006,123(1):43-50. [3] Liao YH,Jee SH,Sheu BC,et al.Increased expression of the natural killer cell inhibitory receptor CD94/NKG2A and CD158b on circulating and lesional T cells in patients with chronic plaque psoriasis.Br J Dermatol,2006,155(2):318-324. [4] Bovenschen HJ,van Vlijmen-Willems IM,van de Kcrkhof Pc,et al.Identification of lesional CD4+CD25+Foxp3+regulatory T cells in Psoriasis.Dermatology,2006,213(2):111-117. [5] Rotsztejn H,Zalewska A,Trznadel-Budzko E,et al.Influence of systemic photochemotherapy on regulatory T cells and selected cytokine production in psoriatic patients:a pilot study.Med Sci Monit,2005,11(12):CR594-598. [6] Lindqvist U,Kristjansson G,Pihl-Lundin I,et al.Patients with psoriatic arthritis have an increased number of lymphocytes in the duodenal mucosa in comparison with patients with psoriasis vulgaris.J Rheumatol,2006,33(5):924-947. [7] Piskin G,Sylva-Steenland RM,Bos JD,et al.n vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis 1esions:enhanced expression in psoriatic skin.J Immunol,2006,176(3):1908-1915. [8] Zheng Y,Danilenko DM,Valdez P,et al.Interleukin-22,a T (H)17 eytokine,mediates IL-23-induced dermal inflammation and acanthosis.Nature,2007,445(7128):648-651. [9] Li HH,Lin YC,Chen PJ,et al.Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis.Br J Dermatol,2005,153(3):591-595. [10] Wei CC,Chen WY,Wang YC,et al.Detection of IL-20 and its receptors on psoriatic skin.Clin Immunol,2005,117(1):65-72. [11] Eriksen KW,Lovato P,Skov L,et al.Increased sensitivity to interferon-alpha in psoriatic T cells.J Invest Dermatol,2005,125(5):936-944. [12] Nestle FO,Conrad C,Tun-Kyi A,et al.Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.J Exp Med,2005,202(1):135-143. [13] Gupta AK,Cherman AM.Efalizumab in the treatment ofpsoriasis.J Cutan Med Surg.2006,10(2):57-68. [14] Goedkoop AY,de Rie MA,Picavet DI,et al.Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis.Arch Dermatol Res,2004,295(11):465-473. [15] Shikiar R,Heffernan M,Langley RG,et al.Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis:patient-reported outcomes from a phase Ⅱ randomized controlled trial.J Dermatolog Treat,2007,18(1):25-31. [16] Krinner EM,Raum T,Petsch S,et al.A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF.Mol Immunol,2007,44(5):916-925. [17] Villadsen LS,Skov L,Dam TN,et al.In situ depletion of CD4 (+)T cells in human skin by Zanolimumab.Arch Dermatol Res,2007,298(9):449-455. [18] Leon F,Contractor N,Fuss I,et al.Antibodies to complement receptor 3 treat established inflammation in murine models of colitis and a novel model of psoriasiform dermatitis.J Immunol,2006,177(10):6974-6982. 通讯作者: